OncLive TV

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Abdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer.

Stacey A. Cohen, MD, discusses the clinical implications of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

Gail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results.

Wassim Abida, MD, PhD, discusses the clinical significance of the results from the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer.

Karim Masrouha, MD, discusses the challenges of surgically removing chordoma tumors.

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer.

Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.

Reva K. Basho, MD, discusses the evolution of therapeutic sequencing in HER2-positive breast cancer.

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.

Gail J. Roboz, MD, discusses recent therapeutics developments in the treatment of patients with acute myeloid leukemia.

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.

Hiromichi Shirasu, MD, discusses the utilization of circulating tumor DNA testing in colorectal cancer.

William Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.

Christopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.

Lisa A. Carey, MD, FASCO, discusses the phase 3 monarchE trial in hormone receptor–positive, HER2-negative breast cancer.

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.